Novo Nordisk A/S $NVO Holdings Lowered by Northstar Asset Management Inc.

Northstar Asset Management Inc. decreased its stake in Novo Nordisk A/S (NYSE:NVO) by 24.1% in the second quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 51,796 shares of the company’s stock after selling 16,450 shares during the quarter. Northstar Asset Management Inc.’s holdings in Novo Nordisk A/S were worth $2,483,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors have also recently bought and sold shares of the stock. Capital Investment Counsel LLC purchased a new position in shares of Novo Nordisk A/S in the fourth quarter worth approximately $3,727,000. Mirae Asset Global Investments Co. Ltd. raised its position in Novo Nordisk A/S by 2,414.4% in the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 297,881 shares of the company’s stock worth $14,280,000 after acquiring an additional 286,034 shares during the period. Trust Co. of Vermont purchased a new position in shares of Novo Nordisk A/S during the 2nd quarter worth $1,250,000. Burkett Asset Management Ltd purchased a new position in shares of Novo Nordisk A/S during the 4th quarter worth $1,823,000. Finally, Myriad Asset Management Advisors LLC bought a new stake in shares of Novo Nordisk A/S during the 2nd quarter valued at $1,846,000. Hedge funds and other institutional investors own 11.54% of the company’s stock.

Novo Nordisk A/S Trading Down 1.4%

Shares of Novo Nordisk A/S stock opened at $45.59 on Friday. Novo Nordisk A/S has a fifty-two week low of $35.12 and a fifty-two week high of $64.16. The company has a debt-to-equity ratio of 0.59, a quick ratio of 0.56 and a current ratio of 0.79. The company has a market capitalization of $203.56 billion, a P/E ratio of 11.15, a P/E/G ratio of 4.17 and a beta of 0.76. The company has a fifty day moving average of $48.03 and a 200 day moving average of $43.90.

Novo Nordisk A/S (NYSE:NVO) last posted its quarterly earnings results on Tuesday, June 30th. The company reported $0.94 EPS for the quarter. Novo Nordisk A/S had a return on equity of 61.20% and a net margin of 35.36%.The business had revenue of $11.98 billion for the quarter. On average, sell-side analysts anticipate that Novo Nordisk A/S will post 3.43 earnings per share for the current fiscal year.

Novo Nordisk A/S Cuts Dividend

The firm also recently announced a dividend, which was paid on Tuesday, August 25th. Investors of record on Monday, August 17th were paid a dividend of $0.5786 per share. This represents a yield of 258.0%. The ex-dividend date of this dividend was Monday, August 17th. Novo Nordisk A/S’s dividend payout ratio (DPR) is 20.05%.

Analysts Set New Price Targets

Several research firms recently weighed in on NVO. Citigroup reiterated a “neutral” rating on shares of Novo Nordisk A/S in a research report on Monday, July 20th. Wall Street Zen cut Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research report on Saturday, June 20th. HSBC reaffirmed a “hold” rating on shares of Novo Nordisk A/S in a research note on Monday, July 6th. Weiss Ratings upgraded Novo Nordisk A/S from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Wednesday, August 5th. Finally, Berenberg Bank set a $47.00 target price on shares of Novo Nordisk A/S in a report on Wednesday, August 12th. Four research analysts have rated the stock with a Buy rating, fourteen have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $64.94.

Novo Nordisk A/S News Roundup

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: China’s drug regulator accepted Novo Nordisk’s application for an oral version of Wegovy, an important regulatory milestone that could broaden access to its obesity treatment and support future growth in a major market. China drug regulator accepts Novo Nordisk’s application for oral Wegovy
• Positive Sentiment: Some investors view Novo Nordisk as potentially undervalued following its selloff. A report also suggests that shifting legal risks surrounding compounded or competing GLP-1 products could improve the outlook for branded treatments such as Ozempic and Wegovy. Novo Nordisk stock may be cheap as GLP-1 legal risks shift
• Neutral Sentiment: Novo Nordisk’s U.S. shares recently traded near $46, below the 50-day average but above the 200-day average. Its relatively low forward valuation may limit downside for value-oriented investors, but the stock’s price-to-earnings-growth ratio indicates that a recovery is not yet fully reflected in earnings expectations.
• Negative Sentiment: Deutsche Bank downgraded Novo Nordisk from Hold to Sell and cut its price target from 290 to 265 Danish kroner. The bank cited doubts about a return to growth, intensifying competition from Eli Lilly, a looming patent-related revenue cliff and weakness in the company’s development pipeline. Deutsche Bank cuts Novo Nordisk to Sell after earnings
• Negative Sentiment: Investor concerns were reinforced by mixed second-quarter results and the late-stage failure of cardiovascular drug candidate Ziltivekimab, which Deutsche Bank reportedly considers effectively removed from the company’s near-term growth prospects. Novo’s 2027 growth rebound faces fresh doubts

About Novo Nordisk A/S

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.